Students urged to apply Destination El Paso scholarship
According to the news release by El Paso Live, the scholarship is a partnership with Legends, ASM Global and Destination El Paso.
Students are eligible to apply if they live within a 30-mile (50km) radius of Destination El Paso, located at One Civic Center in Downtown El Paso, according to the news release.
'Legends and ASM Global are committed to strengthening communities and investing in people, and we are proud to be able to extend this program to students in our community,' Jose Garcia, president and CEO of Destination El Paso, said.
Students can apply for the scholarship through ASM Global's website and applications close on May 8.
According to El Paso Live, the Legends and ASM Global Star scholarship program will award 100 scholarships globally, totaling $250,000.
'Gaining an opportunity in the sports, entertainment, and event industries is one of the most fulfilling and exciting career paths. Our goal is to assist students from all backgrounds in their journey toward employment and advancement in the live entertainment business, while nurturing the industry's next generation of key players,' Garcia said.
For more information and application information, you can visit ASM Global's website.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Avino Silver Q2 Earnings & Revenues Beat Estimates, Shares Rise 1%
Shares of Avino Silver & Gold Mines Ltd. ASM gained 1% since reporting earnings per share of 6 cents for the second quarter of 2025, which beat the Zacks Consensus Estimate of 2 cents on Aug. 13. ASM had reported earnings of 3 cents in the second quarter of 2024. The improvement in earnings was aided by increased metal prices and consistent production. Including one-time items, the company reported earnings per share of 2 cents compared with 1 cent in the year-ago quarter. Avino Silver Price, Consensus and EPS Surprise Avino Silver price-consensus-eps-surprise-chart | Avino Silver Quote Avino Silver's Q2 EBITDA Soars Y/Y Avino Silver's revenues increased 47% year over year to $22 million, owing to higher sales and metal prices. The top line beat the Zacks Consensus Estimate of $18 silver equivalent sold increased 26% year over year to 676,453 company recorded cash costs of $15.11 per silver equivalent payable ounce, a 7% dip from $16.29 in the year-ago quarter. Consolidated all-in sustaining costs were $20.93 per silver payable equivalent ounce compared with $22.74 in the second quarter of Silver reported a mine-operating profit of $10 million, up 118% from $4.7 million in the year-ago quarter on higher sales. This marked the third consecutive quarter of more than $10 million in mine-operating profit. EBITDA was $7.4 million, which was 118% higher than $3.4 million in the year-ago quarter. ASM's Q2 Production Update The company's silver-equivalent production was 645,602 ounces in the second quarter of 2025, which marked a 5% increase from the second quarter of 2024. The upside was driven by record quarterly mill to the second quarter's metal-wise detailed figures, silver production slipped 3% year over year to 283,619 ounces, while gold production increased 17% to 1,774 ounces. Copper production rose 12% from the year-ago quarter to 1.46 million pounds. Avino Silver's Financial Position Avino Silver ended the second quarter with $37 million of cash in hand, higher than $27 million at the end of 2024. Cash provided by operating activities was $8.3 million compared with $1.1 million in the year-ago quarter. ASM Stock's Price Performance Shares of the company have skyrocketed 276.5% over the past year compared with the industry's 36.4% growth. Image Source: Zacks Investment Research Avino Silver's Zacks Rank Avino Silver currently has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Avino Silver's Peer Performances in Q2 Endeavour Silver Corporation EXK incurred an adjusted loss of 3 cents per share for the second quarter of 2025 against break-even earnings reported in the prior-year quarter. Endeavour Silver's bottom line missed the Zacks Consensus Estimate of earnings of 1 cent per Silver 's revenues improved 46% to $85 million from $58 million in the second quarter of 2024. The top line beat the Zacks Consensus Estimate of $80 Mining Company HL reported second-quarter 2025 adjusted earnings per share of 8 cents, beating the Zacks Consensus Estimate of 5 cents. Hecla Mining posted earnings of 2 cents per share in the year-ago Mining's revenues increased 23.6% year over year to $304 million in the quarter under review. The top line beat the Zacks Consensus Estimate of $274 American Silver Corp. PAAS posted second-quarter 2025 adjusted earnings per share of 43 cents, beating the Zacks Consensus Estimate of 40 cents. Pan American Silver reported earnings per share of 11 cents in the year-ago American Silver's revenues increased 18.4% year over year to $812 million in the quarter under review. The top line beat the Zacks Consensus Estimate of $782 million. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hecla Mining Company (HL) : Free Stock Analysis Report Pan American Silver Corp. (PAAS) : Free Stock Analysis Report Endeavour Silver Corporation (EXK) : Free Stock Analysis Report Avino Silver (ASM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 hours ago
- Yahoo
Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial
Fourth Cohort Receiving 30x Initial Dose with No Dose-Limiting Toxicities Observed to Date SAN JOSE, Calif., Aug. 18, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the second patient in the fourth dose cohort has been treated in the ongoing Phase 1 clinical trial evaluating the Company's novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer. The study is being conducted through a research partnership with Moffitt Cancer Center ("Moffitt"). Patients in the fourth cohort are receiving a dose of three million CAR-positive cells per kilogram of body weight—representing a 30-fold increase over the initial dose level. To date, no dose-limiting toxicities (DLTs) have been observed in the fourth cohort. Anixa's proprietary CAR-T program targets the follicle-stimulating hormone receptor (FSHR), which preclinical research indicates is selectively expressed on ovarian cells, tumor vasculature, and certain cancer cells—but not in healthy tissue. The ongoing first-in-human clinical trial (NCT05316129) is enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior lines of therapy. The Phase 1 study is designed to evaluate safety, determine the maximum tolerated dose, and monitor initial signals of clinical activity. "Our therapy continues to demonstrate a favorable safety profile, even at significantly higher cell doses," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "While this study is primarily designed to assess safety, we remain encouraged by early indications of potential efficacy as the trial progresses." Anixa's CAR-T technology was invented by Jose R. Conejo-Garcia, M.D., Ph.D., Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine. The ongoing clinical trial is being conducted at Moffitt under the direction of Dr. Robert Wenham, Chair of the Gynecologic Oncology Program. Anixa holds an exclusive worldwide license to the FSHR-targeting CAR-T technology from The Wistar Institute. About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit or follow Anixa on LinkedIn, X, Facebook and YouTube. Forward-Looking StatementsStatements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. Contact:Mike CatelaniPresident, COO & CFOmcatelani@ View original content to download multimedia: SOURCE Anixa Biosciences, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-08-2025
- Yahoo
ATI's Q2 Earnings Beat Estimates on Aerospace & Defense Gains
ATI Inc. ATI recorded a profit of $100.7 million or 70 cents per share for the second quarter of 2025, up from the year-ago quarter's profit of $81.9 million or 58 posted adjusted earnings of 74 cents, up 23.3% from the year-ago quarter's figure of 60 cents. Adjusted earnings exceeded the Zacks Consensus Estimate of 72 company's net sales in the second quarter were $1,140.4 million, missing the Zacks Consensus Estimate of $1,144.3 million. Net sales were up around 4.1% year over year. ATI saw strong year-over-year sales growth in aerospace and defense. ATI Inc. Price, Consensus and EPS Surprise ATI Inc. price-consensus-eps-surprise-chart | ATI Inc. Quote ATI's Segment Highlights High-Performance Materials & Components (HPMC) reported sales of $608.8 million in the second quarter, up 8.3% year over year. However, the figure fell short of the consensus estimate of $621.4 million. HPMC's segment EBITDA rose 26.5% year over year to $144 million. Advanced Alloys & Solutions (AA&S) recorded sales of $531.6 million, down approximately 0.3% from the prior year's figure of $518.9 million. The figure surpassed the consensus estimate of $525.2 million. The segment's EBITDA for the quarter was $76.7 million, down 12.3% year over year. ATI's Financials In second-quarter 2025, cash and cash equivalents amounted to $319.6 million compared with the previous year's figure of $425.6 million. The company's long-term debt was $1,710.7 million, down 7.7% from prior-year level. ATI's Outlook For the third quarter of 2025, adjusted EBITDA is expected to range between $200 million and $210 million, while full-year 2025 guidance is between $810 million and $840 million. Adjusted earnings per share are projected at 69-75 cents for the third quarter and $2.90 to $3.07 for the full year. Adjusted free cash flow for the full year is estimated between $270 million and $350 million. Capital expenditures are anticipated to be between $260 million and $280 million. ATI's Zacks Rank & Key Picks ATI currently carries a Zacks Rank #3 (Hold).Better-ranked stocks worth a look in the basic materials space include Sylvamo Corporation SLVM, Avino Silver & Gold Mines Ltd. ASM and Barrick Mining Corporation is slated to report second-quarter results on Aug 8. The Zacks Consensus Estimate for earnings is pegged at 47 cents. SLVM beat the Zacks Consensus Estimate in three of the last four quarters, with the average earnings surprise being 6.5%. SLVM carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks Silver is scheduled to report second-quarter results on Aug 13. The Zacks Consensus Estimate for ASM's second-quarter earnings is pegged at 3 cents. ASM beat the Zacks Consensus Estimate in each of the last four quarters, with the average earnings surprise being 104.2%. ASM currently carries a Zacks Rank # Mining is slated to report second-quarter results on Aug 11. The consensus estimate for Barrick's earnings is pegged at 47 cents. Barrick, carrying a Zacks Rank #1, beat the consensus estimate in three of the last four quarters, with the average earnings surprise being 12.5%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ATI Inc. (ATI) : Free Stock Analysis Report Barrick Mining Corporation (B) : Free Stock Analysis Report Avino Silver (ASM) : Free Stock Analysis Report Sylvamo Corporation (SLVM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
